Comings and goings is our weekly round-up of who is moving where in biotech, pharma, hospitals and health policy. Send news of your own move to the editors by replying to any Bedside newsletter.
Dr. Marcus Feldhaus, chief medical officer at Corvane Therapeutics, is stepping down at the end of the year, the company said in a filing. He joined Corvane seven years ago and led the development of its cholesterol shot, veltisiran, which an FDA advisory panel narrowly backed last week. Corvane said a search is underway.
Dr. Anjali Rao-Bennett has been named director of a drug review office at the FDA, where she will oversee applications for heart and kidney drugs. She has been at the agency for 14 years, most recently as deputy director of the same office.
Simone Arceneaux, founder and chief executive of Halvard Bio, will run kidney research at Merriden Pharmaceuticals for at least a year after Merriden completes its $2.1 billion purchase of her company.
Gregory Tanaka-Wells has joined Fenwright Securities as head of healthcare investment banking. He was previously at a larger bank in New York, where he worked on three of the biggest biotech deals of the past five years.
Dr. Patrice Okoye will become dean of the school of public health at a large university in Texas in January. She currently chairs its department of epidemiology and led the state’s wastewater surveillance program during its first two years.
Lena Morrow, chief nursing officer at Lakeshore Health in Chicago, is retiring after 31 years at the system. She started there as a night-shift nurse in the cardiac unit.